Puma Biotechnology Inc (NAS:PBYI)

$ 4.94 -0.195 (-3.8%) Market Cap: 238.30 Mil Enterprise Value: 251.28 Mil PE Ratio: 15.44 PB Ratio: 4.66 GF Score: 59/100

Q1 2024 Puma Biotechnology Inc Earnings Call Transcript
May 02, 2024

$4.96 (+0.20%)

Earnings
Q4 2023 Puma Biotechnology Inc Earnings Call Transcript
Feb 29, 2024

$6.22 (-5.76%)

Earnings
Q3 2023 Puma Biotechnology Inc Earnings Call Transcript
Nov 02, 2023

$2.49 (-6.04%)

Earnings
Q2 2023 Puma Biotechnology Inc Earnings Call Transcript
Aug 03, 2023

$3.52 (-2.49%)

Earnings
Q1 2023 Puma Biotechnology Inc Earnings Call Transcript
May 04, 2023

$2.61 (-0.76%)

Earnings
G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel Transcript
Mar 07, 2023
Q4 2022 Puma Biotechnology Inc Earnings Call Transcript
Mar 02, 2023

$3.98 (-1.00%)

Earnings
Q3 2022 Puma Biotechnology Inc Earnings Call Transcript
Nov 03, 2022

$2.14 (-0.93%)

Earnings
Puma Biotechnology Inc to Discuss the Alisertib Licensing Agreement Call Transcript
Sep 20, 2022
Q2 2022 Puma Biotechnology Inc Earnings Call Transcript
Aug 04, 2022

$3.27 (+5.14%)

Earnings
Q1 2022 Puma Biotechnology Inc Earnings Call Transcript
May 05, 2022

$2.24 (-8.94%)

Earnings
Q4 2021 Puma Biotechnology Inc Earnings Call Transcript
Mar 03, 2022

$2.33 (+4.95%)

Earnings
Q3 2021 Puma Biotechnology Inc Earnings Call Transcript
Nov 04, 2021

$6.39 (-2.89%)

Earnings
Q2 2021 Puma Biotechnology Inc Earnings Call Transcript
Aug 05, 2021

$6.99 (+2.04%)

Earnings
Q1 2021 Puma Biotechnology Inc Earnings Call Transcript
May 06, 2021

$9.68 (+0.41%)

Earnings
Puma Biotechnology Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
Q4 2020 Puma Biotechnology Inc Earnings Call Transcript
Feb 25, 2021

$10.55 (-6.72%)

Earnings
Puma Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Puma Biotechnology Inc at H C Wainwright BioConnect Conference (Virtual) Transcript
Jan 11, 2021
Puma Biotechnology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 10, 2020
Q3 2020 Puma Biotechnology Inc Earnings Call Transcript
Nov 05, 2020

$8.47 (-3.09%)

Earnings
Q2 2020 Puma Biotechnology Inc Earnings Call Transcript
Aug 06, 2020

$10.38 (-4.68%)

Earnings
Puma Biotechnology Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Q1 2020 Puma Biotechnology Inc Earnings Call Transcript
May 07, 2020

$9.88 (-1.00%)

Earnings
Q4 2019 Puma Biotechnology Inc Earnings Call Transcript
Feb 20, 2020

$13.96 (+0.22%)

Earnings
Puma Biotechnology Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Puma Biotechnology Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019
Q3 2019 Puma Biotechnology Inc Earnings Call Transcript
Nov 06, 2019

$7.13 (-1.25%)

Earnings
Q2 2019 Puma Biotechnology Inc Earnings Call Transcript
Aug 08, 2019

$9.21 (+4.54%)

Earnings
Puma Biotechnology Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019
Q1 2019 Puma Biotechnology Inc Earnings Call Transcript
May 09, 2019

$30.02

Earnings
Q4 2018 Puma Biotechnology Inc Earnings Call Transcript
Feb 28, 2019

$27.81 (-2.56%)

Earnings

G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel Transcript

Mar 07, 2023 / 03:30PM GMT

Release Date Price: $2.95 (-1.99%)

Transcript 10-K8-K

Unidentified Analyst

Okay. I think we'll get started. Welcome back to the Cowen Healthcare Conference. Really happy to have -- next up with a panel discussion of various development programs companies in the breast and lung cancer space. And over to my side here, we have Jack Bailey from G1 Therapeutics; Filip Janku, the CMO from Monte Rosa; Eric Poma, CEO of Molecular Templates; Shane Kovacs, the COO and CFO of Olema Oncology; as well as Alan Auerbach, CEO of Puma.

Maybe to start off, we're going to start the conversation with some general topics that hopefully are a bit interactive between the various company representatives. And then we will dive into some company-specific questions. I think Joe is going to lead off with one of the general questions.

Questions & Answers

Unidentified Analyst

Thanks, Mark. And just a reminder for the audience, if you do have any questions for our panelists, feel free to e-mail us at [email protected], and we can try and get those into the discussion. But maybe just to start off, we've seen a couple of instances over the past

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.